TICKERNERD
Menu
LHLHHealthcare · Diagnostics & Research

LH Stock Forecast: Labcorp Holdings, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$368
+2.20% on the day

The 18 Wall Street analysts covering Labcorp Holdings, Inc. hold a median 12-month price target of $355 — -3.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 28 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$26.9B
Ticker Nerd rank
88/ 100
Median analyst target
$355
Analysts covering
18
Revenue$3.7B+5.8% y/y
Operating income$456.7M
Net income$299.1M
Free cash flow$313.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.6%
1M
+19.2%
YTD
+47.8%
1Y
+49.9%
From 52W high
0.0%
From 52W low
+50.8%
$244
$368
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Labcorp Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
88/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Revisions
94
Momentum
79
Quality
76
Issuance
65
Growth
64
Value
62
Accruals
61
Size
7

Volatility (98): The share price has been relatively steady.

Accruals (61): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Jan 26Apr 26Jul 26Oct 26LHHigh $385Median $355Low $293

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
13 Buy4 Hold1 Sell
Low $293Median $355High $385

The green dot is the last close — the median target sits −3.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Sept 2026Truist SecuritiesMaintainsBuy$350 → $365
11 Sept 2026BarclaysMaintainsEqual-Weight—
11 Sept 2026BarclaysMaintainsEqual-Weight$320 → $330
11 Sept 2026UBSMaintainsBuy$361 → $380
11 Sept 2026UBSMaintainsBuy—
4 Aug 2026Piper SandlerMaintainsNeutral$300 → $309
4 Aug 2026Piper SandlerMaintainsNeutral—
3 Aug 2026JP MorganMaintainsOverweight$330 → $360
3 Aug 2026JP MorganMaintainsOverweight—
31 July 2026BarclaysMaintainsEqual-Weight—
31 July 2026BarclaysMaintainsEqual-Weight$290 → $320
31 July 2026Morgan StanleyMaintainsOverweight$308 → $338
31 July 2026Morgan StanleyMaintainsOverweight—
31 July 2026Truist SecuritiesMaintainsBuy$320 → $350
31 July 2026Truist SecuritiesMaintainsBuy—
13 July 2026B of A SecuritiesMaintainsBuy—
13 July 2026B of A SecuritiesMaintainsBuy$300 → $320
13 July 2026BairdMaintainsOutperform$335 → $338
13 July 2026BairdMaintainsOutperform—
8 Apr 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LH appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Labcorp Holdings, Inc. returned +49.9% against +13.6% for the S&P 500, dividends included.

LH vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140150Jan 26Apr 26Jul 26Oct 26LHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.9%
Analysts raising
3
Analysts cutting
0
Fundamentals

Labcorp Holdings, Inc. (LH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
27.4×

Cheaper than 28% of US stocks

Price / sales
1.9×

Cheaper than 53% of US stocks

Price / book
3.1×

Cheaper than 29% of US stocks

EV / EBITDA
14.5×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
5.8%

Higher than 42% of US stocks

Earnings growth (YoY)
25.6%

Higher than 63% of US stocks

Gross margin
29.8%

Higher than 34% of US stocks

Operating margin
12.2%

Higher than 68% of US stocks

Net margin
7.0%

Higher than 64% of US stocks

Returns & dividend
Return on equity
11.7%

Higher than 67% of US stocks

Return on assets
5.5%

Higher than 79% of US stocks

Dividend yield
0.9%

Higher than 69% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Labcorp Holdings, Inc. (LH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Labcorp Holdings, Inc. has a market value of $26.9B and an enterprise value of $33.6B.

  • Revenue in the twelve months to 30 June 2026: $14.3B. The latest quarter grew 5.8% year on year.

  • Net income over the same four quarters: $1.0B, a 7.0% net margin.

  • Diluted earnings per share, trailing twelve months: $12.09.

  • Free cash flow in the twelve months to 30 June 2026: $1.2B, after $483.2M of capital spending.

  • Labcorp Holdings, Inc. spent $701.8M on share buybacks and $239.1M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 80.9M.

  • Trailing P/E: 27.4×; forward P/E: 16.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.87%, paying out 24% of earnings.

  • Labcorp Holdings, Inc. employs 71,000 people — $202K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

LH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
LHLabcorp Holdings, Inc.$26.9B88
DGXQuest Diagnostics, Inc.$27.3B95
MTDMettler-Toledo International, Inc.$34.7B93
GHGuardant Health, Inc.$23.6B57
ILMNIllumina, Inc.$43.6B92
IDXXIDEXX Laboratories, Inc.$44.9B95
MEDPMedpace Holdings, Inc.$19.8B95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Labcorp Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LH news & analysis

Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)

Seeking Alpha · 29 Oct 2026negative

Labcorp raised guidance, prompting a sharp stock rally. The Seeking Alpha author sees a compelling long-term growth story but says the valuation is stretched, with the price-earnings ratio nearing 20, and downgraded the rating.

Why it matters — LH watchers may weigh the improved guidance against concerns that the current valuation exceeds the author’s preferred range for the company’s fundamentals.

Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript

Seeking Alpha · 28 Oct 2026neutral

Seeking Alpha published a transcript of Labcorp Holdings Inc.’s Q3 2026 earnings call. The provided excerpt contains no details about the call’s discussion or results.

Why it matters — LH watchers can refer to the transcript, but the excerpt does not provide information to assess the company’s quarterly performance.

Labcorp Targets Margin Growth, Absorbs Policy Headwinds

Benzinga · 28 Oct 2026positive

Labcorp reported upbeat third-quarter earnings and raised its fiscal outlook. Its stock was trading at a 52-week high.

Why it matters — LH watchers may note the earnings and outlook update alongside the stock’s reported 52-week high.

Labcorp Q3 Earnings Call Highlights

MarketBeat · 28 Oct 2026positive

Labcorp reported third-quarter 2026 revenue growth, margin expansion and double-digit growth in adjusted earnings per share. The company raised the midpoint of its full-year revenue and earnings outlook.

Why it matters — The results and updated outlook provide LH watchers with information about the company’s recent performance and expectations for the full year.

LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View Up

Zacks Investment Research · 28 Oct 2026positive

Labcorp shares rose after the company reported Q3 earnings and revenue above estimates. Both segments delivered growth, margins expanded, and Labcorp raised its 2026 financial outlook.

Why it matters — The results and higher 2026 outlook provide LH watchers with an update on the company’s operating performance and expectations.

FAQ

Frequently asked questions about LH stock

What is the LH stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Labcorp Holdings, Inc. have a median 12-month price target of $355, with estimates ranging from $293 to $385. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LH stock a buy right now?

Of the 18 analysts covering Labcorp Holdings, Inc., 13 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Labcorp Holdings, Inc. 88 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LH?

As at 28 Oct 2026, Labcorp Holdings, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will LH stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies -3.6% from the last close, and Ticker Nerd's factor model ranks Labcorp Holdings, Inc. 88 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LH stock forecast for 2030?

No analyst covering Labcorp Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $293 to $385 over the next 12 months.

How has LH stock performed over the past year?

Labcorp Holdings, Inc. returned +49.9% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Labcorp Holdings, Inc. do?

Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development.

What is the latest news on LH?

The most recent item we track (Seeking Alpha, 29 Oct 2026): "Labcorp Holdings: The Optimism May Be Going Overboard (Rating Downgrade)". Labcorp raised guidance, prompting a sharp stock rally. The Seeking Alpha author sees a compelling long-term growth story but says the valuation is stretched, with the price-earnings ratio nearing 20, and downgraded the rating.

Company

About Labcorp Holdings, Inc.

Labcorp Holdings Inc. is a global life sciences and healthcare company that provides laboratory services to support clinical care, research, and drug development. Labcorp Holdings Inc. serves doctors, hospitals, pharmaceutical companies, researchers, and patients through a broad portfolio that includes routine and specialty diagnostic testing, central laboratory services, and early development research support. Its Diagnostics Laboratories segment covers testing in areas such as oncology, women’s health, autoimmune disease, and neurology, while its Biopharma Laboratory Services segment supports pharmaceutical and biotech clients with laboratory capabilities for clinical trials and development programs. The company plays a key role in healthcare by helping customers generate data used in diagnosis, treatment decisions, and biomedical research.

CEO Mr. Adam H. Schechter · 71,000 employees · United States · https://www.labcorp.com